Compare Tango Therapeutics Inc. (TNGX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Wipro Limited — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Wipro Limited trades at $1.79 (market cap $17.45B). The key difference: Wipro Limited is far larger — about 4.7× Tango Therapeutics Inc.'s market cap, and Wipro Limited pays a 4.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Wipro Limited for 41 Days on average.
| TNGX | WIT | |
|---|---|---|
Market Cap | $3.75B | $17.45B |
Volume | 9,619,106 | 12,096,194 |
Sector | Health | Technology |
52-Week High | $32.90 | $3.06 |
52-Week Low | $7.50 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $2.77B | $15.54B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The company maintains solid fundamentals with $890.88B revenue, 13.92% net margin, and $131.35B net income for 2025. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. However, the stock faces mixed analyst sentiment with only 19% buy ratings and recent earnings misses.
Wipro presents a mixed investment case with reasonable valuation (P/E 13.84) and strong cash flow generation offset by earnings volatility and competitive pressures. The AI transformation offers growth potential, but investors should weigh execution risks against the company's established market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
